ATE537838T1 - Kombinationstherapie mit kloretazin(tm) - Google Patents

Kombinationstherapie mit kloretazin(tm)

Info

Publication number
ATE537838T1
ATE537838T1 AT05745357T AT05745357T ATE537838T1 AT E537838 T1 ATE537838 T1 AT E537838T1 AT 05745357 T AT05745357 T AT 05745357T AT 05745357 T AT05745357 T AT 05745357T AT E537838 T1 ATE537838 T1 AT E537838T1
Authority
AT
Austria
Prior art keywords
nucleoside
vnp40101m
subject
kloretazine
combination therapy
Prior art date
Application number
AT05745357T
Other languages
English (en)
Inventor
Ivan King
Mario Sznol
Michael Belcourt
Li-Mou Zheng
Original Assignee
Vion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc filed Critical Vion Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE537838T1 publication Critical patent/ATE537838T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05745357T 2004-03-26 2005-03-25 Kombinationstherapie mit kloretazin(tm) ATE537838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55656504P 2004-03-26 2004-03-26
PCT/US2005/010152 WO2005094282A2 (en) 2004-03-26 2005-03-25 Combination therapy comprising cloretazinetm

Publications (1)

Publication Number Publication Date
ATE537838T1 true ATE537838T1 (de) 2012-01-15

Family

ID=35064262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05745357T ATE537838T1 (de) 2004-03-26 2005-03-25 Kombinationstherapie mit kloretazin(tm)

Country Status (5)

Country Link
US (1) US7605137B2 (de)
EP (1) EP1804816B1 (de)
CN (1) CN101014353A (de)
AT (1) ATE537838T1 (de)
WO (1) WO2005094282A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1804816B1 (de) 2004-03-26 2011-12-21 Vion Pharmaceuticals, Inc. Kombinationstherapie mit kloretazin(tm)
EA017753B1 (ru) 2007-04-14 2013-02-28 Саузерн Рисерч Инститьют Способы лечения неоплазии при помощи комбинации клофарабина и облучения
CN106933548B (zh) * 2015-12-29 2021-01-12 阿里巴巴集团控股有限公司 全局信息获取、处理及更新、方法、装置和系统

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4175200A (en) * 1975-04-11 1979-11-20 Uniroyal, Inc. N,N-Disubstituted sulfonyl hydrazines
US4447427A (en) * 1979-01-04 1984-05-08 The United States Of America As Represented By The Secretary Of The Army Method for treating bacterial infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones
US4385055A (en) * 1979-01-04 1983-05-24 The United States Of America As Represented By The Secretary Of The Army 2-Acetyl-and 2-propionylpyridine thiosemicarbazones as antimalarials
US4684747A (en) * 1984-12-20 1987-08-04 Yale University N,N'-bis(sulfonyl)hydrazines having antineoplastic activity
US4849563A (en) * 1986-01-21 1989-07-18 Yale University Novel 1-alkyl-1-arenesulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity
US4696938A (en) * 1986-04-25 1987-09-29 Rohm And Haas Company Insecticidal 6-aryl-pyridine thiosemicarbazones
US5101072A (en) * 1989-09-06 1992-03-31 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5214068A (en) * 1989-09-06 1993-05-25 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5256820A (en) * 1991-11-08 1993-10-26 Yale University 1-alkyl-2-acyl-1,2-disulfonylhydrazines
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5637619A (en) * 1995-07-05 1997-06-10 Yale University Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines
US5767134A (en) * 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
US6040338A (en) * 1997-11-03 2000-03-21 Yale University N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents
US6630480B1 (en) * 1999-03-29 2003-10-07 Biochem Pharma Inc. Methods of treating leukemia
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
AU2002211725B2 (en) 2000-10-13 2005-06-30 Vion Pharmaceuticals, Inc. Modified prodrug forms of AP/AMP
US6855695B2 (en) * 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
EP1804816B1 (de) 2004-03-26 2011-12-21 Vion Pharmaceuticals, Inc. Kombinationstherapie mit kloretazin(tm)

Also Published As

Publication number Publication date
WO2005094282B1 (en) 2006-07-20
WO2005094282A2 (en) 2005-10-13
CN101014353A (zh) 2007-08-08
EP1804816A2 (de) 2007-07-11
US20080025984A1 (en) 2008-01-31
WO2005094282A3 (en) 2006-05-11
US7605137B2 (en) 2009-10-20
EP1804816A4 (de) 2009-07-01
EP1804816B1 (de) 2011-12-21

Similar Documents

Publication Publication Date Title
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
TW200502385A (en) Modulation of forkhead box o1a expression
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
TW200621240A (en) Cancer treatments
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
ATE538800T1 (de) Kombinationstherapie zur krebsbehandlung
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
TW200630089A (en) Treatment methods
GB0418388D0 (en) Cell therapy
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
WO2007130501A3 (en) Combination therapy for treatment of cancer
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)